A Randomized Clinical Trial of Anti–IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection

BACKGROUND: Late antibody-mediated rejection (ABMR) is a leading cause of transplant failure. Blocking IL-6 has been proposed as a promising therapeutic strategy. METHODS: We performed a phase 2 randomized pilot trial to evaluate the safety (primary endpoint) and efficacy (secondary endpoint analysi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Am Soc Nephrol
Autori principali: Doberer, Konstantin, Duerr, Michael, Halloran, Philip F., Eskandary, Farsad, Budde, Klemens, Regele, Heinz, Reeve, Jeff, Borski, Anita, Kozakowski, Nicolas, Reindl-Schwaighofer, Roman, Waiser, Johannes, Lachmann, Nils, Schranz, Sabine, Firbas, Christa, Mühlbacher, Jakob, Gelbenegger, Georg, Perkmann, Thomas, Wahrmann, Markus, Kainz, Alexander, Ristl, Robin, Halleck, Fabian, Bond, Gregor, Chong, Edward, Jilma, Bernd, Böhmig, Georg A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Nephrology 2021
Soggetti:
Clinical Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7920172/
https://ncbi.nlm.nih.gov/pubmed/33443079
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2020071106
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi